Mativ (NYSE:MATV) Stock Price Down 3.8%

Mativ Holdings, Inc. (NYSE:MATVGet Free Report)’s stock price dropped 3.8% during mid-day trading on Wednesday . The company traded as low as $17.88 and last traded at $17.94. Approximately 118,163 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 541,967 shares. The stock had previously closed at $18.65.

Mativ Stock Down 1.4 %

The business’s 50 day moving average is $15.45 and its 200-day moving average is $14.34. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.28 and a current ratio of 2.53. The firm has a market capitalization of $998.03 million, a price-to-earnings ratio of -3.18, a price-to-earnings-growth ratio of 2.06 and a beta of 0.74.

Mativ (NYSE:MATVGet Free Report) last posted its earnings results on Wednesday, February 21st. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.07. The business had revenue of $452.30 million for the quarter, compared to analyst estimates of $472.10 million. Mativ had a negative net margin of 13.47% and a positive return on equity of 6.70%. Equities analysts anticipate that Mativ Holdings, Inc. will post 1.5 EPS for the current fiscal year.

Mativ Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Friday, March 8th were given a $0.10 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $0.40 annualized dividend and a yield of 2.18%. Mativ’s dividend payout ratio is -7.07%.

Insiders Place Their Bets

In related news, Director Jeffrey Keenan purchased 3,000 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were bought at an average cost of $16.06 per share, for a total transaction of $48,180.00. Following the transaction, the director now directly owns 312,000 shares of the company’s stock, valued at approximately $5,010,720. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.01% of the company’s stock.

Institutional Trading of Mativ

Several institutional investors have recently made changes to their positions in MATV. UBS Group AG raised its stake in shares of Mativ by 2.1% in the first quarter. UBS Group AG now owns 42,849 shares of the company’s stock worth $920,000 after acquiring an additional 874 shares during the last quarter. Swiss National Bank raised its stake in shares of Mativ by 0.8% during the third quarter. Swiss National Bank now owns 120,512 shares of the company’s stock worth $1,719,000 after buying an additional 900 shares during the last quarter. LPL Financial LLC raised its stake in shares of Mativ by 8.4% during the second quarter. LPL Financial LLC now owns 12,714 shares of the company’s stock worth $192,000 after buying an additional 989 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in Mativ by 93.7% in the fourth quarter. Quadrant Capital Group LLC now owns 2,385 shares of the company’s stock valued at $37,000 after buying an additional 1,154 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Mativ by 18.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,254 shares of the company’s stock valued at $126,000 after buying an additional 1,314 shares during the period. 94.95% of the stock is currently owned by institutional investors and hedge funds.

Mativ Company Profile

(Get Free Report)

Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.

Read More

Receive News & Ratings for Mativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mativ and related companies with MarketBeat.com's FREE daily email newsletter.